Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-02-26
2010-11-16
Kumar, Shailendra (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07834054
ABSTRACT:
The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
REFERENCES:
patent: 4999378 (1991-03-01), Fujii et al.
patent: 5254731 (1993-10-01), Zimmer et al.
patent: 5972978 (1999-10-01), Andersen et al.
patent: 6211197 (2001-04-01), Belley et al.
patent: 6960685 (2005-11-01), Watkins et al.
patent: 7276612 (2007-10-01), Verner et al.
patent: 2004/0053908 (2004-03-01), Funahashi et al.
patent: 2004/0077726 (2004-04-01), Watkins et al.
patent: 2007/0293540 (2007-12-01), Verner et al.
patent: 2201968 (1973-08-01), None
patent: 0084236 (1983-07-01), None
patent: 0394440 (1990-10-01), None
patent: 3-215470 (1991-09-01), None
patent: WO-95-05358 (1995-02-01), None
patent: WO-00-20371 (2000-04-01), None
patent: WO-01-14331 (2001-03-01), None
patent: WO-01-38322 (2001-05-01), None
patent: WO-02-26703 (2002-04-01), None
patent: WO-02-30879 (2002-04-01), None
patent: WO-03-013493 (2003-02-01), None
patent: WO-03-070691 (2003-08-01), None
patent: WO-2004-013130 (2004-02-01), None
Carter et al., Chemotherapy of Cancer, second edition, John Wiley & Sons, N.Y., N.Y., 1981, pp. 362-365.
U.S. Appl. No. 11/940,260, filed Nov. 14, 2007, Verner et al.
U.S. Appl. No. 11/940,273, filed Nov. 14, 2007, Verner et al.
Brzozowski, Z. et al., “Derivatives of 2-Mercapobenzenesulphonamide XI. Synthesis and Some Pharmacological Properties of 2-{2—[2-(3,4,5-Trimethoxybenzamido)Ethylthio]Benzenesulphonyl} Guanadines,” Acta Poloniae Pharmaceutica-Drug Research 50(4-5):345-352 (1993).
Carter et al., Chemotherapy of Cancer, 2nded., John Wiley & Sons, N.Y., N.Y. 1981, pp. 362-365.
Hines, J.W. and Stammer, C.H., “3-Hydroxyisoxazole-5-hydroxamic Acid,” J. Med. Chem 20(7):965-967 (1977).
LaVoie, R., “Design and Synthesis of a Novel Class of Histone Deacetylase Inhibitors,” Bioorg. Med. Chem. Ltrs. 11:2847-2850 (2001).
Uesato, S., “Novel Histone Deacetylase Inhibitors: N-Hydroxycarboxamides Possessing a Terminal Bicyclic Aryl Group,” Bioorg. Med. Chem. Ltrs. 12:1347-1349 (2002).
Watanabe, S. et al., “Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosynthesis,” Eur. J. Med. Chem. 29:675-686 (1994).
Buggy Joseph J.
Verner Erik J.
Kumar Shailendra
Pharmacyclics Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Hydroxamates as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxamates as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamates as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4193744